Navigation Links
For Patients on Statins, Study Finds Filling 90 Day Supply Prescriptions through Mail Service Compared to Retail Pharmacy is Associated with Less Waste
Date:4/27/2011

ST. PAUL, Minn., April 27, 2011 /PRNewswire/ -- A new study shows 90-day statin drug claims filled through a mail service pharmacy are associated with less waste than a 90-day supply from a retail pharmacy. The findings of the study by Prime Therapeutics (Prime), a thought leader in pharmacy benefit management, will be presented at the Academy of Managed Care Pharmacy's 23rd Annual Meeting and Showcase, taking place in Minneapolis, Minn. April 27-29.

Waste occurs when patients stop taking their medication, as a result of a dosage or drug switch, before the entire supply is used. Increasingly, patients with chronic conditions are moving to 90-day prescriptions, and previous studies have shown those receiving a 90-day prescription adhere better to their medications compared to those with a 30-day prescription.

"As an increasing number of patients move to 90-day prescriptions, this study shows we have an opportunity to reduce medication waste as a result of a dosage or drug switch if patients fill their prescription through mail service," said Patrick Gleason, PharmD, director of Clinical Outcomes Assessment, Prime.

For the study, researchers reviewed the claims of 51,261 Blue Cross and Blue Shield (BCBS) members who received statin prescriptions to identify those with overlapping claims. Researchers reviewed prescriptions filled from the second quarter of 2009 to the second quarter of 2010, via a retail pharmacy 30-day supply, a retail pharmacy 90-day supply and a mail service 90-day supply.

The results of the study show 3,996 of the 51,261 members (7.8 percent) with a statin claim had at least one day of waste, and the average days of waste was 24. Those receiving a 90-day supply via retail pharmacy had significantly higher waste (p<0.001) than those receiving their prescription through 30-day retail supply or 90-day mail service. Among those who received their medication through 90-day retail supply, those who were unable to use t
'/>"/>

SOURCE Prime Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. Many Heart Attack Patients Dont Get Best Emergency Treatment
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company ... on the Mylan N.V. ("Mylan") (NASDAQ: MYL ) ... Perrigo. "Our views of Mylan,s offer to ... be, based on our Board,s careful reflection of the ... on the limited choices that Mylan has allowed its ...
(Date:8/28/2015)... , FARUM, Denmark and ... On July 31, 2015 the US Food and Drug ... treatment of Major Depressive Disorder in adult patients who have ... the current episode. TMS is a non-invasive technique for stimulating ... patients suffering from Major Depressive Disorder. The procedure has been ...
(Date:8/28/2015)... , Aug. 28, 2015 ... and Dr. Ra from Biostar , Published in ... 30% increase of lifespan through multiple IV administration of ... vitality, and life expectancy found , Commercialization within ... have determined the possibility that adult mesenchymal stem cells ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2
... Therapeutics,(OTC Bulletin Board: ECTE) today announced positive ... Transdermal Continuous Glucose Monitoring (tCGM),System in patients ... Echo,s non-invasive,Symphony tCGM System consists of its ... Prelude(TM) SkinPrep System, which,incorporates leading-edge, needle-free skin ...
... TRIANGLE PARK, N.C., July 27 Timothy Mastro,MD, ... on August 1st,as Senior Director of Research, will ... for HIV prevention at the,International AIDS Conference in ... Prophylaxis: Current,and Planned Trials," will examine ongoing and ...
Cached Medicine Technology:Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 2Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 3Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 4HIV Prevention Expert Dr. Timothy Mastro Speaks on Future of Pre-Exposure Prophylaxis at International AIDS Conference 2
(Date:8/29/2015)... ... , ... Next weekend is Labor Day weekend, the last bash of the ... this year). For IT security personnel, it should also mark the perfect time to ... costly than a simple headache. , Joe Caruso, founder and CEO-CTO of Global ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences announced today ... and Arterosil HP, and that all claims and counterclaims have been irrevocably dismissed. ... (VHS) in the United States District Court for the Southern District of Texas ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce Investment Commissioner ... they are applying for, they are unable to pass the initial drug test and ... testing policies in order to be able to hire long-term, skilled talent. (1) Will ...
(Date:8/28/2015)... Baltimore, MD (PRWEB) , ... August 28, 2015 , ... ... reduction system from Merz, received FDA clearance for results that last for two ... clearance is exciting news for patients who are looking for a long-lasting, effective solution ...
(Date:8/28/2015)... ... 28, 2015 , ... “ Frequentz ” was featured on NewsWatch as part ... on the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch ... allows businesses to track product movement from beginning to end. , Businesses benefit greatly ...
Breaking Medicine News(10 mins):Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Track Product Movement from Beginning to End with Frequentz 2
... the new central clearing house for an ambitious ongoing ... of biomedical data to make it more accessible to ... Resources, a component institute of the National Institutes of ... support the Biomedical Informatics Research Network Coordinating Center (BIRNCC) ...
... offer hope of better hearing for people who suffer ... the non-profit educational organization Better Hearing Institute (BHI). The ... States and Canada found that six out of ten ... hearing aids and two of ten reported major relief. ...
... for surrogates enrolling loved ones in research studies , , ... support having their family members enroll them in disease ... decision themselves, a new study says. , ... would prove especially helpful in studying people with Alzheimer,s ...
... Jan. 21 Health Integrated, a pioneer in targeted ... has joined the fast-growing company as Senior Vice President ... Health Integrated,s Solutions Group which will extend on the ... customers, their members, and network of providers. "Vic is ...
... between tobacco smoke and cancer deaths beyond lung ... study from a UC Davis researcher, suggesting that increased ... estimated. , The epidemiological analysis, published online in ... percent of the cancer death burden among Massachusetts men ...
... 21 Nu Skin Enterprises, Inc. (NYSE: NUS ... year-end 2008 financial results prior to the market opening on ... will host a conference call with the investment community later ... the call, participants can expect to hear management review past ...
Cached Medicine News:Health News:USC awarded $22.2M NIH national biomedical informatics infrastructure coordinating center contract 2Health News:Hearing Aids Offer Hope for Those Who Suffer from Persistent 'Ringing in the Ears,' Better Hearing Institute Survey Finds 2Health News:Hearing Aids Offer Hope for Those Who Suffer from Persistent 'Ringing in the Ears,' Better Hearing Institute Survey Finds 3Health News:Hearing Aids Offer Hope for Those Who Suffer from Persistent 'Ringing in the Ears,' Better Hearing Institute Survey Finds 4Health News:Decide for Me When I Can't, Most People Say 2Health News:Victor Dragon Joins Health Integrated to Lead Solutions Group 2Health News:UC Davis study links smoking with most male cancer deaths 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: